Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Wave Life Sciences, Inc.WVE · Entity 4976 | Director | August 18, 2020 | August 20, 2020 |
| enGene Therapeutics Inc.ENGN · Entity 6638 | Chief Global Comm. Ofc. | June 16, 2025 | June 16, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Wave Life Sciences, Inc.
Report date August 18, 2020 · Filed August 20, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.13 · Expires 2025-08-18 | Direct | 10,500 |
Reported balance
After 2020-08-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-08-18 · Grant · Acquired 10,500 · Balance 10,500 F1: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2021 annual general meeting or August 18, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2021 annual general meeting or August 18, 2021.
enGene Therapeutics Inc.
Report date June 16, 2025 · Filed June 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.31 · Expires 2035-06-16 | Direct | 400,000 |
Reported balance
After 2025-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-16 · Grant · Acquired 400,000 · Balance 400,000 F1: Non-qualified stock option grant awarded as an inducement award outside of the Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan in accordance with NASDAQ Listing Rule 5635(c)(4). This option vests at 25% on May 27, 2026, which is the first anniversary of the employment commencement date, with the remaining portion to vest monthly over the remaining three years, subject to the reporting person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: Non-qualified stock option grant awarded as an inducement award outside of the Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan in accordance with NASDAQ Listing Rule 5635(c)(4). This option vests at 25% on May 27, 2026, which is the first anniversary of the employment commencement date, with the remaining portion to vest monthly over the remaining three years, subject to the reporting person's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2025 Filed Jun 16, 2025 18:40 UTC | enGene Therapeutics Inc. ENGN · Entity 6638 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $3.31 | $0.00 |
DisclosureSEC source: 0000929638-25-002252 · form4.xml · derivative · entry 1 Pott Amy · CIK 0001787363 · Chief Global Comm. Ofc. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Shares · 400,000 shares Expires 2035-06-16 F1 · derivative.exercise_date: Non-qualified stock option grant awarded as an inducement award outside of the Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan in accordance with NASDAQ Listing Rule 5635(c)(4). This option vests at 25% on May 27, 2026, which is the first anniversary of the employment commencement date, with the remaining portion to vest monthly over the remaining three years, subject to the reporting person's continued service. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 22:32 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0000899243-20-023086 · doc4.xml · derivative · entry 1 Pott Amy · CIK 0001787363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Ordinary Shares · 10,500 shares Expires 2025-08-18 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2021 annual general meeting or August 18, 2021. Read SEC document |
| September 04, 2019 Filed Sep 6, 2019 22:43 UTC | Wave Life Sciences, Inc. WVE · Entity 4976 | GrantShare Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0000899243-19-023032 · doc4.xml · derivative · entry 1 Pott Amy · CIK 0001787363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Ordinary Shares · 21,000 shares Expires 2024-09-04 F1 · derivative.exercise_date: The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 25% of the shares on September 4, 2020 and the remainder vests quarterly thereafter until September 4, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.